Marker Therapeutics reported a narrowed net loss of $5.0 million for the six months ended June 30, 2026. This result marks an improvement from the $8.5 million loss recorded during the same period in 2025.
Lower research and development spending primarily drove the reduced loss. R&D expenses for the first half of the year fell to $4.3 million from $7.3 million year-over-year.
Despite the lower spending, management issued a warning regarding the company's ability to continue as a going concern. Marker held $11.9 million in cash, cash equivalents, and restricted cash as of June 30, 2026.
The company expects current funds to sustain operations into the second quarter of 2027. Marker is actively seeking additional capital or grant funding to advance its clinical programs.